A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3784-3791

  Rangasamy, Sampathkumar ^a   Srinivasan, Ramprasad ^a   Maestas, Joann ^a   McGuire, Paul G ^a   Das, Arup ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b New Mexico VA Health Care System   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CASPASE 3; VASCULAR ENDOTHELIAL CADHERIN; ANGPT1 PROTEIN, RAT; CADHERIN; GLUCOSE; LEUKOCYTE ANTIGEN; MESSENGER RNA; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CELL STRUCTURE; CONTROLLED STUDY; DIABETIC RETINOPATHY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CAPILLARY PERMEABILITY; CELL CULTURE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FLUORESCENT ANTIBODY TECHNIQUE; IMPEDANCE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RETINA BLOOD VESSEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; UPREGULATION; VASCULAR ENDOTHELIUM;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CADHERINS; CAPILLARY PERMEABILITY; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRIC IMPEDANCE; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUCOSE; HUMANS; HYPERGLYCEMIA; MALE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TYROSINE; UP-REGULATION;

EID: 79955953053     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6386     Document Type: Article

References (50)

1. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290:2057-2060.
2. Geiger B, Ayalon O. Cadherins Ann Rev Cell Biol. 1992;8:307-333.
3. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353:839-841.
4. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-365.
5. Biester S, Ziemssen F, Ulrich Bartz-Schmidt K, Gelisken F. Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema? Graefes Arch Clin Exp Ophthalmol. 2009;247:1575-1577.
6. Peters S, Cree IA, Alexander R, et al. Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability. Cytokine. 2007;40:144-150.
7. Jin SW, Patterson C. The opening act: vasculogenesis and the origins of circulation. Arterioscler Thromb Vasc Biol. 2009;29:623-629.
8. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
9. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor by secretion-trap expression cloning. Cell. 1996;87:1161-1169.
10. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand and angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103: 4150-4156.
11. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476-481.
12. Das A, Fanslow W, Cerretti D, Warren E, Talarico N, McGuire P. Angiopoietin/Tek interactions regulate mmp-9 expression and retinal neovascularization. Lab Invest. 2003;83:1637-1645.
13. Pfister F, Feng Y, vom Hagen F, et al. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes. 2008;57:2495-2502.
14. Feng Y, vom Hagen F, Pfister F, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost. 2007;97:99-108.
15. Yao D, Taguchi T, Matsumura T, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007; 282:31038-31045.
16. Ohashi H, Takagi H, Koyama S, et al. Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vis. 2004;10:608-617.
17. Vincent PA, Xiao K, Buckley KM, Kowalzzyk AP. VE-cadherin: adhesion at arm's length. Am J Physiol Cell Physiol. 2004;286: C987-C997.
18. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999; 98:147-157.
19. Wang Y, Jin G, Miao H, Li JY, Usami S, Chien S. Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras. Proc Natl Acad Sci USA. 2006;103:1774-1779.
20. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008;121:2115-2122.
21. Gavard J, Gutkind JS. VE-cadherin and claudin-5: it takes two to tango. Nat Cell Biol. 2008;10:883-885.
22. Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes. 2007;56:2380-2387.
23. Gavard J. Breaking the VE-cadherin bonds. FEBS Lett. 2009;583:1-6.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-Ct method. Methods. 2001;25:402-408.
25. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001;42:789-793.
26. Giaever I, Keese CR. A morphological biosensor for mammalian cells. Nature. 1993;366:591-592.
27. Gilles RJ, Didler N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem. 1986;159:109-113.
28. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1-32.
29. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoformselective inhibitor. Diabetes. 1997;46:1473-1480.
30. Murata T, Ishibashi T, Kahalil A. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
31. Sang DN, D'Amore PA. Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia. 2008;51:1570-1573.
32. Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol. 2005;89: 480-483.
33. Hammes HP, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53:1104-1111.
34. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-293.
35. Litkouhi B, Kwong J, Lo CM, et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of clostridium perfringens enterotoxin. Neoplasia. 2007;9:304-314.
36. Garcia J, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689-701.
37. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006;312:630-641.
38. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol and Cell Biol. 2009;29:2011-2022.
39. Rutter GA, Tavaré JM, Palmer DG. Regulation of mammalian gene expression by glucose. News Physiol Sci. 2000;15:149-155.
40. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29-38.
41. Yao D, Taguchi T, Matsumura T, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem. 2007; 282:31038-1045.
42. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000;184:275-284.
43. Melgar-Lesmes P, Tugues S, Ros J, et al. Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats. Gut. 2009;58:285-292.
44. Dudek SM, Garcia J. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol. 2001; 91:1487-1500.
45. Vestweber D. VE-cadherin. The major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Artherioscler Thromb Vasc Biol. 2008;28:223-232.
46. Alcaide P, Newton G, Auerbach S, et al. p120-Catenin regulates leukocyte transmigration through an effect on VE-cadherin phosphorylation. Blood. 2008;112:2770-2779.
47. Turowski P, Martinelli R, Crawford R, et al. Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration. J Cell Sci. 2008;121:29-37.
48. Covington MD, Bayless KJ, Burghardt RC, Davis GE, Parrish AR. Ischemia-induced cleavage of cadherins in NRK cells: evidence for a role of metalloproteinases. Am J Physiol Renal Physiol. 2005; 289:F280-F288.
49. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the b-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223-1233.
50. Nottebaum AF, Cagna G, Winderlich M, et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J Exp Med. 2008;205: 2929-2945.